United Therapeutics Corp Patent: Treatment of Pulmonary Hypertension with Prostacyclin-Treated Stem Cells

According to GlobalData’s company profile on United Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. United Therapeutics‘s grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11839631B2) discloses a method for treating pulmonary hypertension by administering a combination of a first prostacyclin and mesenchymal stem cells (MSCs) to a subject suffering from the condition. The MSCs are pre-treated with a second prostacyclin before administration, with the option of using the same prostacyclin for both treatments. The first prostacyclin can be treprostinil, and it can be co-administered with MSCs or administered before or after MSCs.

Furthermore, the method allows for the ex vivo contact of MSCs with the second prostacyclin, along with the option of adding a growth factor during this process. The MSCs can be obtained from the subject themselves, offering a personalized approach to treatment. This method is particularly beneficial for patients suffering from pulmonary arterial hypertension, providing a novel and potentially effective therapeutic strategy for managing this condition.

To know more about GlobalData’s detailed insights on United Therapeutics, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies